Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 14996911 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Mariner DJ, Davis MA, Reynolds AB (2004) EGFR signaling to p120-catenin through phosphorylation at Y228. J Cell Sci 117, 1339-50 14996911
Download Sites

Y228-p - CTNND1 (mouse)
Orthologous residues
CTNND1 (human): Y228‑p, CTNND1 iso3 (human): Y228‑p, CTNND1 iso4 (human): Y228‑p, CTNND1 iso22 (human): Y127‑p, CTNND1 (mouse): Y228‑p, CTNND1 iso3 (mouse): Y228‑p, CTNND1 (rat): Y228‑p
Characterization
 Methods used to characterize site in vivo electrophoretic mobility shift, mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  breast cancer, colorectal cancer, colorectal carcinoma, pancreatic cancer, pancreatic carcinoma
 Relevant cell lines - cell types - tissues:  3T3 (fibroblast), A431 (epithelial), HCT116 (intestinal), HT-29 (intestinal), MDA-MB453 (breast cell), MDA-MB468 (breast cell), MIA PaCa-2 (pancreatic), SKBr3 (breast cell), SYF (fibroblast), T47D (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE Src (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Src (human) transfection of constitutively active enzyme, pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme, phospho-antibody, transfection of inactive enzyme, transfection of wild-type enzyme
 Comments:  not the only kinase as SYF cells still exhibit robust pY228 in +EGF
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
SU6656 EGF inhibit treatment-induced increase slight decrease
SU6656 decrease
AG1478 decrease
EKI-785 decrease
PP1 decrease
low Ca(2+) decrease


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.